证券代码：603079 证券简称：圣达生物 公告编号：2025-014 浙江圣达生物药业股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江圣达生物药业股份有限公司（以下简称"公司"）第四届董事会第十 六次会议（以下简称"本次会议"）于2025年4月24日在公司会议室以现场表决 方式召开。本次会议已于2025年4月14日以电子邮件方式通知全体董事、监事及 高级管理人员。本次会议由公司董事长洪爱女士主持，应到董事9人，实到董事 9人；公司监事、高级管理人员列席了本次会议。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》、《浙 江圣达生物药业股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，会议形成的决议合法有效。 二、董事会会议审议情况 (一) 审议通过《2024年度董事会工作报告》 表决结果：同意9票，反对0票，弃权0票。 本议案尚需提交公司股东大会审议。 (二) 审议通过《2024年度总经理工作报告》 表决结果：同意9票，反对0票， ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-016 浙江圣达生物药业股份有限公司 关于公司2024年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024年度利润分配方案为：不派发现金红利，不送红股，不以资本公积 转增股本。 公司2024年实施股份回购，以现金方式回购股份视同现金分红的金额为 13,113,100.00元（不含印花税、交易佣金等交易费用）。 本次利润分配方案已经公司第四届董事会第十六次会议和第四届监事会 第十五次会议审议通过，尚需提交公司2024年年度股东大会审议。 公司不触及《上海证券交易所股票上市规则（2024年4月修订）》（以下 简称《股票上市规则》）第9.8.1条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经天健会计师事务所（特殊普通合伙）审计，公司2024年度合并报表中实 现 归 属 于 母 公 司 股 东 的 净 利 润 29,424,490.05 元 ， 母 公 司 实 现 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 203,225,651.02, representing a year-on-year increase of 9.95% compared to CNY 184,829,589.97 in the same period last year[4]. - Net profit attributable to shareholders of the listed company reached CNY 21,709,484.85, a significant increase of 469.35% from CNY 3,813,060.72 in the previous year[4]. - The basic and diluted earnings per share were both CNY 0.13, reflecting a 550.00% increase from CNY 0.02 in the same period last year[5]. - The weighted average return on equity increased by 1.4 percentage points to 1.71% compared to 0.31% in the previous year[5]. - Total revenue for Q1 2025 reached ¥203,225,651.02, an increase of 9.5% compared to ¥184,829,589.97 in Q1 2024[20]. - Net profit for Q1 2025 was ¥23,418,911.36, significantly up from ¥5,303,881.02 in Q1 2024, representing a growth of 341.5%[21]. - Operating profit for Q1 2025 was ¥27,633,346.93, compared to ¥7,505,502.29 in Q1 2024, indicating a substantial increase[21]. - Basic earnings per share for Q1 2025 were ¥0.13, compared to ¥0.02 in Q1 2024, indicating a significant improvement[22]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -21,121,737.08, worsening from CNY -7,787,016.92 in the same period last year[4]. - Cash flow from operating activities was ¥190,106,736.12 in Q1 2025, up from ¥178,966,766.36 in Q1 2024, reflecting a growth of 6.3%[24]. - The total cash outflow from operating activities was $228,918,640.38, compared to $198,347,829.36 previously, resulting in a net cash flow from operating activities of -$21,121,737.08, worsening from -$7,787,016.92[25]. - The company's current assets totaled approximately 663.38 million RMB, a decrease from 708.77 million RMB on December 31, 2024[15]. - The company's cash and cash equivalents decreased from approximately 315.62 million RMB to 244.56 million RMB over the same period[15]. - The ending cash and cash equivalents balance was $222,366,162.95, down from $247,275,484.71, reflecting a decrease of approximately 10.1%[26]. Investments and Fundraising - The company plans to issue up to 51,356,687 A-shares, raising a total of no more than 500 million RMB, to invest in the production of 3 billion soft capsules and 3 billion solid preparations, as well as a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[13]. - The company has adjusted its fundraising amount for the A-share issuance from 500 million RMB to 267.61 million RMB[13]. - Cash inflow from investment activities totaled $88,480,311.40, significantly up from $23,717,143.12, indicating a substantial increase in investment recovery[25]. - The cash outflow from investment activities was $131,675,436.43, compared to $108,287,452.50, leading to a net cash flow from investment activities of -$43,195,125.03, an improvement from -$84,570,309.38[25]. Shareholder Information - The major shareholders include Zhejiang Shengda Group Co., Ltd. with a 26.51% stake and Tian Tai Wan Jian Investment Development Center with an 18.28% stake[10]. - The employee stock ownership plan aims to hold up to 872,500 shares, with a total funding not exceeding 4.9995 million RMB[14]. - The stock purchase price for the employee stock ownership plan is set at 5.73 RMB per share[14]. - The company has not yet implemented the employee stock ownership plan as of March 31, 2025[14]. Research and Development - Research and development expenses rose to ¥10,162,625.24 in Q1 2025, up from ¥7,896,868.68 in Q1 2024, reflecting a 28.7% increase[21]. - The company has not disclosed any new product developments or market expansion strategies in this report[8]. Asset Changes - The total assets at the end of the reporting period were CNY 1,806,478,130.51, a slight increase of 1.19% from CNY 1,785,311,152.08 at the end of the previous year[5]. - The company’s fixed assets decreased slightly from approximately 432.02 million RMB to 424.76 million RMB[16]. - The company’s intangible assets increased from approximately 225.58 million RMB to 227.64 million RMB[16]. - Total liabilities decreased to ¥499,084,898.78 from ¥501,336,831.71, showing a reduction of 0.5%[18]. - Shareholders' equity increased to ¥1,307,393,231.73 from ¥1,283,974,320.37, marking a growth of 1.8%[18].

Financial Performance - The net profit attributable to the parent company for 2024 is RMB 29,424,490.05, with the parent company achieving a net profit of RMB 13,084,701.15[6]. - The company's operating revenue for 2024 reached ¥827,401,959.68, representing a year-on-year increase of 13.75% compared to ¥727,405,727.98 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥29,424,490.05, a significant recovery from a loss of ¥54,062,928.21 in 2023[25]. - The net cash flow from operating activities increased by 129.55% to ¥147,878,103.30 in 2024, up from ¥64,421,472.79 in 2023[25][27]. - The company's total assets as of the end of 2024 were ¥1,785,311,152.08, reflecting a 3.85% increase from ¥1,719,185,557.88 in 2023[26]. - Basic earnings per share for 2024 improved to ¥0.17, compared to a loss of ¥0.32 per share in 2023[26]. - The weighted average return on equity for 2024 was 2.35%, up from -4.19% in 2023, indicating improved profitability[26]. Dividend Policy - The company plans to distribute no cash dividends, no bonus shares, and no capital reserve conversion to share capital for the 2024 fiscal year[7]. - The total cash dividend amount accounted for 44.57% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which was CNY 29,424,490.05[150]. - The company has established a three-year shareholder dividend return plan for 2023-2025, emphasizing reasonable returns to investors[146]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, high customer concentration, exchange rate fluctuations, and changes in the macroeconomic environment[10]. - Raw material price volatility poses a significant risk to the company's profitability, as raw materials constitute a large portion of production costs[115]. - The sales revenue from the top five customers accounted for 20.47%, 21.09%, 24.07%, and 31.99% of total revenue in 2021, 2022, 2023, and 2024 respectively, indicating a high customer concentration risk[116]. - The company is exposed to risks from macroeconomic changes, which could impact consumer demand and overall profitability[117]. Market and Product Development - The company focused on enhancing its product sales structure, particularly in the pharmaceutical-grade vitamin sector and biological preservatives, contributing to revenue growth[25]. - The company plans to continue expanding its market presence in high-value products, particularly in biological preservatives and functional ingredients[25]. - The company completed registrations for biotin in India, EU CEP, and South Korea, laying the groundwork for further market expansion[36]. - The company is focusing on cost reduction and efficiency improvement through innovative production and technology upgrades[35]. Research and Development - The company is committed to increasing R&D investment and maintaining close cooperation with universities and research institutions[38]. - Research and development expenses amounted to 43.76 million yuan, reflecting a 1.95% increase from the previous year[55]. - The company has 48 ongoing research projects and has obtained 8 national patents during the reporting period[53]. - The company is focusing on synthetic biology research and has built platforms for strain construction and fermentation[53]. Environmental Compliance - The company has implemented a comprehensive environmental management system, certified by ISO14001, ensuring compliance with pollution control regulations[181]. - The company has no reported administrative penalties for environmental issues during the reporting period, indicating strong compliance[178]. - The company is committed to environmental compliance, conducting at least 3 manual samples for various pollutants, including toluene and sulfuric acid, every six months[170]. - The company has established a dedicated environmental protection department to oversee compliance and pollution prevention efforts[181]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[120]. - The company has held 3 shareholder meetings during the reporting period, ensuring compliance with legal procedures and equal rights for all shareholders[119]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[120]. - All directors participated in the board meetings, with no instances of continuous absence from meetings[133]. Employee Engagement - The company has a total of 1,035 employees, including 711 production personnel and 172 technical personnel[142]. - The company approved the 2024 Employee Stock Ownership Plan, which aims to enhance employee engagement and retention[154]. - The company has implemented a dual-channel administrative and technical salary management assessment model to enhance employee motivation and responsibility[143]. Strategic Initiatives - The company plans to invest a total of RMB 499.87 million in the first phase of the "Vitamin Series Products and Raw Material Drug Industry Upgrade Project"[106]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting a deal worth up to 100 million[127]. - The management team emphasized a focus on sustainability initiatives, allocating 10 million towards eco-friendly practices[130].

一、 会议召开和出席情况 证券代码：603079 证券简称：圣达生物 公告编号：2025-013 浙江圣达生物药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)股东大会召开的时间：2025 年 4 月 23 日 重要内容提示： (二)股东大会召开的地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 本次会议是否有否决议案：无 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：《关于延长公司向特定对象发行 A 股股票股东大会决议有效期的 议案》 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 92,732,653 | 99.6215 | 229,344 | 0.2463 | 122,900 | ...

浙江圣达生物药业股份有限公司 浙江天册律师事务所 关于 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼邮编 310007 电话：0571 8790 111 传真：0571 8790 1500 https://www.tclawfirm.com/ 法律意见书 浙江天册律师事务所 关于浙江圣达生物药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：浙江圣达生物药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江圣达生物药业股份有限公 司（以下简称"圣达生物"或"公司"）的委托，指派本所律师参加公司 2025 年第 一次临时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国证券 法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公 司法》"）和《上市公司股东会规则》（以下简称"《股东会规则》"）等有关法 律、行政法规、规章和其他规范性文件的要求以及《浙江圣达生物药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人 ...

Group 1 - The vitamin sector experienced a decline of 1.97% on April 16, with a net outflow of 183 million yuan from main funds, where 4 stocks rose and 26 stocks fell [1] - The companies with the highest net outflow of main funds included China Resources Sanjiu (588.49 million yuan), Xingqi Eye Medicine (313.44 million yuan), Shengda Biology (188.84 million yuan), North China Pharmaceutical (183.74 million yuan), and Nengte Technology (181.81 million yuan) [1] Group 2 - The top stock by net inflow was Huayuan Biological, with a net inflow of 32.28 million yuan and a price increase of 0.29% [2] - New Hec (21.80 yuan) saw a decline of 1.71% with a net inflow of 16.02 million yuan, while Brother Technology (4.02 yuan) experienced a significant drop of 6.07% with a net inflow of 9.80 million yuan [2] - Other notable declines included Zhejiang Medicine (-1.23%), Hendi Pharmaceutical (-1.37%), and Weixin Kang (-1.80%), all showing negative net inflows [2]

证券代码：603079 浙江圣达生物药业股份有限公司 2025 年第一次临时股东大会会议材料 二〇二五年四月 浙江圣达生物药业股份有限公司 2025 年第一次临时股东大会会议材料 目录 | 2025 | 年第一次临时股东大会会议议程 1 | | --- | --- | | 2025 | 年第一次临时股东大会会议须知 3 | | 议案一：关于延长公司向特定对象发行 | A 股股票股东大会决议有效期 | | 的议案 5 | | | 议案二：关于提请股东大会延长授权董事会全权办理本次向特定对象 | | | 发行 A | 股股票相关事宜的议案 7 | 浙江圣达生物药业股份有限公司 2025 年第一次临时股东大会会议议程 一、会议时间 现场会议：2025 年 4 月 23 日(星期三)下午 13:30 网络投票：2025 年 4 月 23 日(星期三)采用上海证券交易所网络 投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的 交易时间段，即 2025 年 4 月 23 日 9:15-9:25，9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-15:0 ...

圣达生物（603079）4月10日在互动平台表示，据了解，公司主要维生素产品生物素和叶酸，均在此次 美国关税豁免清单中，对公司生产经营不会造成重大影响。 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-012 浙江圣达生物药业股份有限公司 关于股东减持股份结果暨权益变动触及1%的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东持股的基本情况 本次减持计划实施前，浙江圣达生物药业股份有限公司（以下简称"公司"）5%以上大股东天台万健投 资发展中心（有限合伙）（以下简称"万健投资"）持有公司股份32,771,141股，占公司总股本比例为 19.14%，万健投资与其一致行动人浙江圣达集团有限公司（以下简称"圣达集团"）、浙江鸿博企业管理 有限公司（以下简称"浙江鸿博"）、朱勇刚合计持有公司股份94,259,216股，占公司总股本的55.06%。 ● 减持计划的实施结果情况 公司于2024年12月28日披露了《浙江圣达生物药业股份有限公司股东减持股份计划公告》（公告编号： 2024-063），万健投资拟于减持计划公告之日起15个交易日后的3个月内，通过集中竞价、大宗交易方 式减持公司股份不超过5,135,668股，减持比例不超过 ...